Marine-derived omega-3 polyunsaturated fatty acid complex, principally eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)
A lipid extract of cold-water marine fish tissue containing the long-chain omega-3 polyunsaturated fatty acids eicosapentaenoic acid and docosahexaenoic acid, with established regulatory approval for severe hypertriglyceridemia and a broad but heterogeneous evidence base spanning cardiovascular risk reduction, systemic inflammation, mood disorders, and neurocognitive support.
Abstract
Fish oil is a complex lipid extract derived from the tissue of cold-water marine fish species (principally anchovy, sardine, mackerel, herring, and menhaden) and is the predominant dietary and supplemental source of the long-chain omega-3 polyunsaturated fatty acids eicosapentaenoic acid (EPA, C20:5n-3) and docosahexaenoic acid (DHA, C22:6n-3). These two fatty acids serve as precursors for specialized pro-resolving mediators (resolvins, protectins, maresins), compete with arachidonic acid for cyclooxygenase and lipoxygenase substrate pools to shift eicosanoid production from pro-inflammatory series-2 prostaglandins and series-4 leukotrienes toward less inflammatory or anti-inflammatory series-3 prostaglandins and series-5 leukotrienes, modulate cell membrane phospholipid composition and lipid raft organization, activate the anti-inflammatory transcription factor peroxisome proliferator-activated receptor gamma (PPARgamma), signal through the G protein-coupled receptor GPR120, and influence ion channel conductance and cardiac electrophysiology. The pharmacological interest in fish oil spans more than five decades, originating with the epidemiological observations of Bang and Dyerberg in Greenland Inuit populations in the early 1970s and progressing through multiple large-scale randomized controlled trials including GISSI-Prevenzione (1999), JELIS (2007), VITAL (2019), REDUCE-IT (2019), and STRENGTH (2020). Icosapent ethyl, a purified EPA ethyl ester, received an expanded FDA indication in 2019 for cardiovascular risk reduction in statin-treated patients with elevated triglycerides and established cardiovascular disease or diabetes, based on the REDUCE-IT trial demonstrating a 25 percent relative risk reduction in major adverse cardiovascular events. The STRENGTH trial, which tested a combined EPA and DHA carboxylic acid formulation, was terminated early for futility with no cardiovascular benefit observed, generating ongoing debate regarding the differential efficacy of EPA-only versus EPA plus DHA preparations and the potential confounding role of mineral oil placebo in REDUCE-IT. Fish oil pharmacokinetics are governed by the chemical form of the omega-3 fatty acids (triglyceride, ethyl ester, free fatty acid, or phospholipid), with triglyceride and free fatty acid forms demonstrating superior bioavailability compared to ethyl esters, particularly under low-fat dietary conditions. Absorption requires pancreatic lipase-mediated hydrolysis and micellar solubilization; peak plasma EPA and DHA concentrations are achieved at approximately 5 to 8 hours post-dose, and steady-state tissue incorporation requires 4 to 12 weeks of daily supplementation. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.